139 related articles for article (PubMed ID: 22981641)
21. Effects of TRK-820, a selective kappa opioid receptor agonist, on rat schizophrenia models.
Yoshikawa S; Hareyama N; Ikeda K; Kurokawa T; Nakajima M; Nakao K; Mochizuki H; Ichinose H
Eur J Pharmacol; 2009 Mar; 606(1-3):102-8. PubMed ID: 19374836
[TBL] [Abstract][Full Text] [Related]
22. Long-term efficacy and safety of nalfurafine hydrochloride on pruritus in chronic liver disease patients: Patient-reported outcome based analyses.
Kamimura K; Yokoo T; Kamimura H; Sakamaki A; Abe S; Tsuchiya A; Takamura M; Kawai H; Yamagiwa S; Terai S
PLoS One; 2017; 12(6):e0178991. PubMed ID: 28604788
[TBL] [Abstract][Full Text] [Related]
23. Clinical Profiles of Nalfurafine Hydrochloride for the Treatment of Pruritus Patients.
Miyamoto Y; Oh T; Aihara E; Ando A
Handb Exp Pharmacol; 2022; 271():455-472. PubMed ID: 33201326
[TBL] [Abstract][Full Text] [Related]
24. Effects of atypical kappa-opioid receptor agonists on intrathecal morphine-induced itch and analgesia in primates.
Ko MC; Husbands SM
J Pharmacol Exp Ther; 2009 Jan; 328(1):193-200. PubMed ID: 18842704
[TBL] [Abstract][Full Text] [Related]
25. One year long-term study on abuse liability of nalfurafine in hemodialysis patients.
Ueno Y; Mori A; Yanagita T
Int J Clin Pharmacol Ther; 2013 Nov; 51(11):823-31. PubMed ID: 24040851
[TBL] [Abstract][Full Text] [Related]
26. The kappa-opioid receptor agonist, nalfurafine, blocks acquisition of oxycodone self-administration and oxycodone's conditioned rewarding effects in male rats.
Zamarripa CA; Patel TR; Williams BC; Pareek T; Schrock HM; Prisinzano TE; Freeman KB
Behav Pharmacol; 2020 Dec; 31(8):792-797. PubMed ID: 32804774
[TBL] [Abstract][Full Text] [Related]
27. Drug-Drug Interactions of a Novel κ-Opioid Receptor Agonist, Nalfurafine Hydrochloride, Involving the P-Glycoprotein.
Ando A; Sasago S; Ohzone Y; Miyamoto Y
Eur J Drug Metab Pharmacokinet; 2016 Oct; 41(5):549-58. PubMed ID: 26058994
[TBL] [Abstract][Full Text] [Related]
28. Combination of Clinically Utilized Kappa-Opioid Receptor Agonist Nalfurafine With Low-Dose Naltrexone Reduces Excessive Alcohol Drinking in Male and Female Mice.
Zhou Y; Kreek MJ
Alcohol Clin Exp Res; 2019 Jun; 43(6):1077-1090. PubMed ID: 30908671
[TBL] [Abstract][Full Text] [Related]
29. Characterization of the chloroquine-induced mouse model of pruritus using an automated behavioural system.
Tarrasón G; Carcasona C; Eichhorn P; Pérez B; Gavaldà A; Godessart N
Exp Dermatol; 2017 Nov; 26(11):1105-1111. PubMed ID: 28605064
[TBL] [Abstract][Full Text] [Related]
30. Comparison of Pharmacological Properties between the Kappa Opioid Receptor Agonist Nalfurafine and 42B, Its 3-Dehydroxy Analogue: Disconnect between
Cao D; Huang P; Chiu YT; Chen C; Wang H; Li M; Zheng Y; Ehlert FJ; Zhang Y; Liu-Chen LY
ACS Chem Neurosci; 2020 Oct; 11(19):3036-3050. PubMed ID: 32897695
[TBL] [Abstract][Full Text] [Related]
31. Antipruritic Effect of Nalbuphine, a Kappa Opioid Receptor Agonist, in Mice: A Pan Antipruritic.
Inan S; Dun NJ; Cowan A
Molecules; 2021 Sep; 26(18):. PubMed ID: 34576988
[TBL] [Abstract][Full Text] [Related]
32. Investigation of gastrin-releasing peptide as a mediator for 5'-guanidinonaltrindole-induced compulsive scratching in mice.
Inan S; Dun NJ; Cowan A
Peptides; 2011 Feb; 32(2):286-92. PubMed ID: 21126550
[TBL] [Abstract][Full Text] [Related]
33. Targeting Itch with Ligands Selective for κ Opioid Receptors.
Cowan A; Kehner GB; Inan S
Handb Exp Pharmacol; 2015; 226():291-314. PubMed ID: 25861786
[TBL] [Abstract][Full Text] [Related]
34. Suppression of acute herpetic pain-related responses by the kappa-opioid receptor agonist (-)-17-cyclopropylmethyl-3,14beta-dihydroxy-4,5alpha-epoxy-beta-[n-methyl-3-trans-3-(3-furyl) acrylamido] morphinan hydrochloride (TRK-820) in mice.
Takasaki I; Suzuki T; Sasaki A; Nakao K; Hirakata M; Okano K; Tanaka T; Nagase H; Shiraki K; Nojima H; Kuraishi Y
J Pharmacol Exp Ther; 2004 Apr; 309(1):36-41. PubMed ID: 14711930
[TBL] [Abstract][Full Text] [Related]
35. Essential structure of opioid κ receptor agonist nalfurafine for binding to κ receptor 1: synthesis of decahydroisoquinoline derivatives and their pharmacologies.
Nagase H; Imaide S; Yamada T; Hirayama S; Nemoto T; Yamaotsu N; Hirono S; Fujii H
Chem Pharm Bull (Tokyo); 2012; 60(8):945-8. PubMed ID: 22863695
[TBL] [Abstract][Full Text] [Related]
36. Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study.
Yagi M; Tanaka A; Namisaki T; Takahashi A; Abe M; Honda A; Matsuzaki Y; Ohira H; Yoshiji H; Takikawa H;
J Gastroenterol; 2018 Oct; 53(10):1151-1158. PubMed ID: 29663077
[TBL] [Abstract][Full Text] [Related]
37. Essential structure of opioid κ receptor agonist nalfurafine for binding to the κ receptor 2: synthesis of decahydro(iminoethano)phenanthrene derivatives and their pharmacologies.
Nagase H; Imaide S; Hirayama S; Nemoto T; Fujii H
Bioorg Med Chem Lett; 2012 Aug; 22(15):5071-4. PubMed ID: 22742909
[TBL] [Abstract][Full Text] [Related]
38. Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study.
Kumagai H; Ebata T; Takamori K; Muramatsu T; Nakamoto H; Suzuki H
Nephrol Dial Transplant; 2010 Apr; 25(4):1251-7. PubMed ID: 19926718
[TBL] [Abstract][Full Text] [Related]
39. Involvement of GRK2 in modulating nalfurafine-induced reduction of excessive alcohol drinking in mice.
Zhou Y; Liang Y
Neurosci Lett; 2021 Aug; 760():136092. PubMed ID: 34197905
[TBL] [Abstract][Full Text] [Related]
40. Nalfurafine hydrochloride to treat pruritus: a review.
Inui S
Clin Cosmet Investig Dermatol; 2015; 8():249-55. PubMed ID: 26005355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
